Small Cell Lung Cancer (SCLC)

Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.

Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.

Tarlatamab plus chemo/IO showed a 71% objective response rate and promising safety for patients with ES-SCLC in the DeLLphi-303 study.

Those with limited-stage small cell lung cancer who had elevated ProGRP levels at baseline had worse OS and PFS outcomes vs those with normalized levels.

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Biomarker research is needed to better ascertain patient benefit with tarlatamab among those with relapsed extensive-stage small cell lung cancer.

Data from the phase 3 IMforte trial support the FDA approval of maintenance lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer.

A real-world, retrospective analysis showed that CRS and ICANS occurred in 48% and 16% of patients with ES-SCLC who were treated with tarlatamab.

Biomarker research may better elucidate clinical benefit and identify mechanisms of resistance with tarlatamab in extensive-stage small cell lung cancer.

The frontline treatment algorithm in SCLC is poised to look “radically different” in the upcoming years, according to Anne Chiang, MD, PhD.

In patients with ES-ECLC treated with chemotherapy and immunotherapy, stereotactic body radiation therapy did not significantly improve overall survival.

In patients with LS-SCLC who were ineligible for a prophylactic cranial irradiation, toripalimab appeared to decrease the progression of brain metastases.

Future biomarker analysis will include correlation of efficacy with SLFN11 expression and with markers of DNA damage repair.

Cisplatin/etoposide and carboplatin/etoposide achieved median OS of 8.8 months and 7.8 months, respectively, in those with extensive-stage small cell lung cancer.

Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

Lurbinectedin achieved an ORR of 27% in all patients with extensive-stage small cell lung cancer in the phase 4 Jazz Emerge 402 study.

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.

Results from the DeLLphi-303 trial showed sustained efficacy and safety with tarlatamab plus anti–PD-1 treatment for patients with extensive-stage SCLC.

Rates of grade 3 or 4 AEs with durvalumab were similar across subgroups, with serious AEs more frequent in patients 70 years or older with ES-SCLC.

The confirmed overall response rate with ABB-706 was 77% in patients with relapsed/refractory small cell lung cancer who received 2 prior lines of therapy.

Leveraging #WCLC25, lung oncologists spoke about the presentations they’re most looking forward to at the upcoming conference.

The median overall survival with atezolizumab plus carboplatin and etoposide was 10.6 months in patients with extensive-stage small cell lung cancer.

The biomarker NLR may not be suitable for prognosis prediction in older patients with small cell lung cancer, according to findings from this real-world study.

No treatment-related deaths were observed with radiotherapy for extensive-stage small cell lung cancer, and most adverse effects were grade 1 or 2.